| Recruiting | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Ca NCT07227597 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) NCT07139990 | University of Texas Southwestern Medical Center | Phase 1 |
| Not Yet Recruiting | A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunothe NCT06982287 | Yong Fang | — |
| Terminated | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) NCT06939036 | Ariceum Therapeutics GmbH | Phase 1 / Phase 2 |
| Not Yet Recruiting | Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 NCT07022301 | First Affiliated Hospital of Wannan Medical College | Phase 2 |
| Recruiting | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung NCT06954246 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC NCT06348797 | Sichuan University | Phase 1 |
| Not Yet Recruiting | Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lu NCT06851819 | Hebei Medical University Fourth Hospital | Phase 2 |
| Not Yet Recruiting | Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Tre NCT06825208 | Nanjing First Hospital, Nanjing Medical University | — |
| Not Yet Recruiting | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and NCT06786312 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC NCT06739928 | Guangzhou Institute of Respiratory Disease | Phase 2 |
| Recruiting | Liposomal Irinotecan and Apatinib in ES-SCLC NCT06749691 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low NCT06610734 | Sichuan University | Phase 2 |
| Not Yet Recruiting | Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lu NCT06648200 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung NCT06429696 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients NCT05703971 | Genprex, Inc. | Phase 1 / Phase 2 |
| Recruiting | First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC NCT05745350 | Xiaorong Dong | Phase 2 |
| Unknown | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy NCT06187740 | Fudan University | Phase 1 |
| Active Not Recruiting | Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cance NCT05856695 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Recruiting | IN10018 Combination Therapy in Treatment-naïve ES-SCLC NCT06030258 | InxMed (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer NCT05680922 | Legend Biotech USA Inc | Phase 1 |
| Recruiting | Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung NCT05384015 | Fundación GECP | Phase 2 |
| Not Yet Recruiting | Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients NCT05066945 | Xiangya Hospital of Central South University | — |
| Terminated | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer NCT05027867 | Kartos Therapeutics, Inc. | Phase 2 |
| Unknown | A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC NCT04967625 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Completed | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease NCT04462276 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Unknown | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small C NCT04659785 | Tianjin Medical University Second Hospital | Phase 1 / Phase 2 |
| Unknown | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC NCT03994744 | Hunan Cancer Hospital | Phase 2 |
| Active Not Recruiting | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer NCT03923270 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer NCT03755115 | Henan Cancer Hospital | Phase 2 |
| Completed | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer NCT03325816 | Georgetown University | Phase 1 / Phase 2 |
| Unknown | Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer NCT03253068 | Wakayama Medical University | Phase 2 |
| Completed | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer NCT03059667 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Recruiting | Molecular Analysis and Treatment Options of SCLC NCT05945745 | Shanghai Chest Hospital | — |
| Unknown | Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) NCT02179528 | Peking University Cancer Hospital & Institute | Phase 2 |
| Terminated | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer NCT00003496 | Burzynski Research Institute | Phase 2 |